All In Biotech

Drug Trial Radar · NCT05454098

Clifutinib Food Effect Study in Healthy Subjects

A Food Effect Phase I Study of the Clifutinib in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 8, 2022

Primary completion

Dec 8, 2022

Study completion Dec 8, 2022

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate to determine the effect of food on the PK of a single dose of 40 mg Clifutinib in healthy subjects.

Conditions

  • Acute Myeloid Leukemia in Children

Interventions

  • Clifutinib with fed stateDrug

    40 mg Clifutinib with food

  • Clifutinib with fasted stateDrug

    40 mg Clifutinib without food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 4 weeks
  2. AUC0-∞Time frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.